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Macrolide antibiotics bind in the nascent peptide exit tunnel of the bacterial ribosome and
prevent polymerization of specific amino acid sequences, selectively inhibiting translation of a
subset of proteins. Because preventing translation of individual proteins could be beneficial
for the treatment of human diseases, we asked whether macrolides, if bound to the eukar-
yotic ribosome, would retain their context- and protein-specific action. By introducing a single
mutation in rRNA, we rendered yeast Saccharomyces cerevisiae cells sensitive to macrolides.
Cryo-EM structural analysis showed that the macrolide telithromycin binds in the tunnel of
the engineered eukaryotic ribosome. Genome-wide analysis of cellular translation and bio-
chemical studies demonstrated that the drug inhibits eukaryotic translation by preferentially
stalling ribosomes at distinct sequence motifs. Context-specific action markedly depends on
the macrolide structure. Eliminating macrolide-arrest motifs from a protein renders its
translation macrolide-tolerant. Our data illuminate the prospects of adapting macrolides for
protein-selective translation inhibition in eukaryotic cells.
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Many human diseases result from expression of unwantedproteins1–3. While the most common therapies for suchdiseases are based on blocking the functions of the
undesirable proteins, this approach mitigates their harmful effect
but does not eliminate the culprit. Inhibiting the production of a
malicious protein could be a better strategy than targeting its
activity. To achieve this goal, significant efforts have been
invested in developing mRNA-targeting approaches for selective
destruction of specific mRNAs or blocking their translation4.
However, very limited research has been dedicated towards
finding molecules, that could curb the production of specific
proteins by acting upon the ribosome. The lack of interest for
undertaking such task could be justified by the traditional notion
that ribosome-targeting compounds indiscriminately prevent
ribosomes from synthesizing all proteins. Therefore, the discovery
of PF846, a small molecule that binds to eukaryotic ribosomes
and selectively inhibits translation of only a subset of polypep-
tides, including the therapeutically-significant protein PCSK9
involved in cholesterol homeostasis, came as a big and welcomed
surprise5,6. Illuminating biochemical and structural studies have
shown that PF846 binds in the nascent peptide exit tunnel
(NPET) of the large ribosomal subunit and interferes with
translation of several specific nascent polypeptides, that assume
an idiosyncratic conformation in the tunnel6,7. However, because
many details of the mechanism of PF846 action remain unknown,
predicting the proteins whose synthesis would be inhibited by this
compound would be a difficult task.
Even though the concept of selective inhibition of eukaryotic
translation by ribosome-targeting small molecules emerged only
recently, it has been long recognized for antibiotics that act upon
the bacterial ribosome. Over four decades ago it was found that
inducible resistance to macrolide antibiotics is regulated by pro-
grammed translation arrest relying on the ability of the drugs to
stop ribosomes at specific mRNA codons, while allowing for
unimpeded translation through the preceding ones8,9. More
recent studies have shown that in fact many drugs that target the
bacterial ribosome act in a context-specific manner, causing
translation arrest at specific sites in mRNA, where the nascent
peptide sequence, tRNA nature or mRNA structure are conducive
to the antibiotic action (reviewed in the ref. 10). Yet, the
ribosome-targeting antibiotics whose context-selective action is
best understood are the macrolides11.
All macrolide antibiotics, from the prototype of this class,
erythromycin (ERY), to those of later generations, e.g., teli-
thromycin (TEL) or solithromycin (SOL)12 (Fig. 1), bind in the
NPET of the bacterial ribosome, close to the peptidyl transferase
center (PTC)13–16. They establish interactions with several rRNA
residues, including the adenosine at position 2058 of the 23S
rRNA (Escherichia coli numbering) which, while conserved in
bacteria, is replaced with guanine in eukaryotes (G2400 in the
yeast Saccharomyces cerevisiae 25S rRNA) (Supplementary Fig. 1a,
b), and is thought to be the key determinant of the bacterial
selectivity of macrolide action14. Because the bulky macrolide
molecule narrows the lumen of the NPET, these antibiotics were
initially thought to completely block the passage of any nascent
polypeptide and to only allow the synthesis of peptides a few
amino acids long17,18. Subsequent studies have shown, however,
that the growing protein chain can be threaded through the
macrolide-obstructed NPET, and that macrolides selectively
abolish production of specific proteins by preventing the ribosome
from polymerizing specific amino acid sequences11,19–22.
Remarkably, the context-specificity of the macrolide action is not
based on the inability of some nascent polypeptides to bypass the
antibiotic in the NPET. Instead, NPET-bound macrolides interfere
with peptide bond formation when the bacterial ribosome
attempts to synthesize specific amino acid motifs23–27. In addition,
the spectrum of the macrolide arrest motifs, and hence the range
of the inhibited proteins, is defined by the chemical structure of
the drug bound in the NPET of the bacterial ribosome11,19,22,28.
Context-specificity and protein-selectivity of macrolide action
in bacteria make this class of antibiotics a promising platform for
developing selective inhibitors of eukaryotic translation. The
prospect of such an approach hinges, however, on the macrolides
retaining their context-selectivity and protein-selectivity of inhi-
bition of protein synthesis in a eukaryotic cell. Unfortunately,
little of what has been learned about macrolide action in bacteria
could be extrapolated to eukaryotic translation, because the
structures and functional properties of NPETs in bacterial and
eukaryotic cytoplasmic ribosomes are substantially different29–33
(Supplementary Fig. 1b, c). Furthermore, whether macrolides can
actually bind in the eukaryotic ribosomal NPET remains unclear,
especially considering that mutation of the key discriminating



































































Fig. 1 Macrolide antibiotics. Chemical structures of the main macrolide antibiotics used in this study. The numbering of the macrolactone atoms is shown
on the ERY structure. C5-desosamine sugars and alkyl-aryl side chains of the extended macrolides are indicated by black and red rectangles, respectively.
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Here, we used biochemical and structural analyses to explore
whether macrolide antibiotics retain their inhibitory activity and
context-specificity of action when bound to the eukaryotic (yeast)
ribosome. We show that engineered yeast cytoplasmic ribosomes
with the G2400A mutation are capable of binding macrolides,
which contain an extended side chain and that the binding mode
of such compounds in the NPET is analogous to that on the
bacterial ribosome. We further show that macrolide binding to
the 80S ribosome inhibits translation in vivo and in vitro.
Genome-wide Ribo-seq studies revealed that in eukaryotic cells,
macrolides interfere with protein synthesis in a context-specific
way, with some of the prevalent arrest motifs overlapping with
those in bacteria, while others being specific for the eukaryotic
80S ribosome. We found that minor changes in the polypeptide-
coding sequence can drastically alter the sensitivity of protein
translation towards a particular macrolide. We also show that by
altering the structure of the macrolide antibiotics bound to the
eukaryotic ribosome, it is possible to modulate their effect upon
synthesis of individual proteins.
Results
A single rRNA mutation sensitizes yeast cells and cytoplasmic
80S ribosomes towards extended macrolide antibiotics. A pre-
vious work had shown that the 25S rRNA G2400A mutation
(A2058 in E. coli; through the rest of the text, the E. coli numbering
is shown in parentheses) in the macrolide binding site, which
replaced the eukaryote-specific guanine with bacteria-specific ade-
nine, did not render yeast 80S ribosomes sensitive to ERY34. We
reasoned that newer and more active macrolides such as TEL or
SOL (Fig. 1), with extended side chains that establish additional
interactions in the NPET of the bacterial ribosome15,35,36, could
perhaps bind to the G2400A mutant yeast ribosomes. Therefore, we
engineered the G2400A mutation de novo in the S. cerevisiae strain
NOY891, where the rRNA-encoding RDN locus on chromosome
XII is deleted and rRNA is expressed from a plasmid37,38 (see
“Methods” section). Primer extension analysis confirmed that the
cytoplasmic 80S ribosomes in the resulting strain contained exclu-
sively the mutant G2400A 25S rRNA (Supplementary Fig. 2a). In
agreement with the previous report34, the engineered G2400A
mutant yeast remained resistant to ERY and the closely related
azithromycin (AZI). However, TEL and SOL completely abolished
the growth of the mutant at concentrations below 200 µg/ml (TEL)
or below 50 µg/ml (SOL) (Fig. 2a and Supplementary Table 1). The
growth arrest was likely caused by inhibition of protein synthesis
because exposure of the mutant yeast cells to SOL resulted in a
rapid decline of incorporation of L-[35S]-methionine into newly
synthesized polypeptides (Fig. 2b). Thus, the G2400A mutation in
25S rRNA of the large subunit of the eukaryotic cytoplasmic
ribosome sensitized yeast to the extended macrolide antibiotics. We
used the engineered mutant to explore the mode of binding of this
class of inhibitors to the 80S ribosome, and the effects of macrolides
upon translation in the eukaryotic cell.
Extended macrolides bind in the exit tunnel of the mutant
yeast ribosome. To verify that extended macrolides inhibit pro-
tein synthesis in the mutant yeast cells by acting upon ribosomes,
we carried out binding studies using radiolabeled [14C]-SOL.
While wild-type (wt) ribosomes were essentially impervious to
binding of SOL, ribosomes with the G2400A mutation showed a
significantly increased affinity to the drug, allowing binding with
an apparent dissociation constant in the sub-micromolar range
(Kd= 0.26 µM ± 0.09) (Fig. 2c). To further analyze whether
binding of SOL and TEL takes place in the NPET of the mutant
eukaryotic ribosome, we analyzed drug-rRNA interactions by
chemical RNA probing. In bacteria, NPET-bound macrolides
shield A2058 and A2059 in the 23S rRNA from modification by
dimethylsulfate (DMS)39–41. In mutant (but not wt) yeast ribo-
somes, SOL and TEL protected the two equivalent rRNA residues,
A2400 and A2401, from DMS modification (Fig. 2d and Sup-
plementary Fig. 2b) revealing binding of these antibiotics in the
NPET of the 80S ribosome. ERY and AZI that lacked the alkyl-
aryl side chain present in the extended macrolides afforded only
marginal protection of these residues (Supplementary Fig. 2c),
corroborating a very weak binding of these antibiotics, which
therefore, were excluded from the subsequent experiments.
While revealing the general location of the macrolide binding
site in the mutant yeast ribosome, the results of rRNA probing are
unable to reveal the atomic interactions and the exact orientation
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Fig. 2 Macrolide antibiotics bind to the mutant yeast ribosome and inhibit protein synthesis and cell growth. a SOL arrests growth of the G2400A
mutant S. cerevisiae cells. Plots show the growth of mutant cells in the absence of the drug (filled black circles) or after addition of 8× MIC of SOL (open
gray circles). The inlet shows that wt yeast is resistant to SOL. The graphs represent results of two independent experiments with individual data points
indicated. b Residual protein synthesis in wt (squares) and G2400A mutant (circles) yeast cells exposed to SOL. Translation was assessed by measuring
incorporation of L-[35S]-methionine into polypeptides after exposure of cells for 10min to different concentrations of SOL. L-[35S]-methionine incorporation
in the untreated mutant cells was set to 100%. The data points of two independent experiments are indicated by squares (wt) and circles (G2400A
mutant). c Equilibrium binding of [14C]-SOL to wt (squares) or G2400A mutant (circles) ribosomes. The data are presented as mean values of three
independent experiments; error bars show standard deviation. d SOL and TEL protect A2400 and A2401 of the 25S rRNA from chemical modification. The
gel shows the primer extension analysis the 25S rRNA extracted from the untreated or dimethyl sulfate (DMS)-modified G2400A 80S ribosomes
incubated without or with the antibiotics. The position of the cDNA bands corresponding to the nucleotide residues A2400 and A2401 are indicated by the
arrows. The chemical modification of wt ribosomes in the presence of SOL and TEL and that of mutant ribosomes in the presence of ERY and azithromycin
are shown in Supplementary Fig. 2b, c, respectively. The uncropped gel can be found in the Source data file. The result is a typical representative of two
independent experiments.
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of the drugs in the 80S ribosome NPET, which can be
dramatically affected by the distinct architectures of ribosomes
from different species42 (Supplementary Fig. 1). To understand
the precise binding mode of the extended macrolides in the yeast
ribosome, we determined the cryo-EM structure of the mutant
G2400A ribosome in complex with TEL with an average
resolution of 3.1 Å (Supplementary Fig. 3). The resolution was
further improved with focused refinement on the large 60S
subunit (Supplementary Fig. 3), leading to a final reconstruction
of the yeast 60S-TEL complex (Fig. 3a) with an average resolution
of 2.9 Å and extending to 2.5 Å within the core of the particle
(Supplementary Fig. 4a–d and Supplementary Table 2). The
density for TEL observed within the NPET of the 60S subunit was
well-resolved, enabling an unambiguous placement of the 14-
membered macrolactone ring, C5-desosamine sugar and the
C10–C11 alkyl–aryl side chain (Fig. 3b and Supplementary
Fig. 4e). TEL binds within the NPET of the yeast large ribosomal
subunit with desosamine sugar extending towards the PTC and
placed adjacent to 25S rRNA nucleotides A2400 (2058) and
A2401 (2059) (Fig. 3c), consistent with the DMS protection
Fig. 3 Cryo-EM structure of TEL bound to the yeast ribosome. a Transverse section of the cryo-EM map density (gray) of the large (60S) subunit of the
yeast G2400A mutant ribosome with TEL (salmon) bound within the NPET. b Isolated cryo-EM density for TEL (gray mesh) with fitted molecular model
for TEL. The similarly-oriented chemical structure of TEL is shown for reference. c TEL bound within the NPET with the surrounding nucleotides of the 25S
rRNA (gray) and His133 residue of uL22 protein (purple). The N1 of A2400(A2058) forms a hydrogen bond interaction to the hydroxyl group of the
desosamine sugar of TEL and a water molecule (W1) mediates interaction of the desosamine’s dimethylamine with the N6 of A2400(A2058), as was also
observed in bacteria43. The alkyl–aryl sidechain of TEL stacks upon the base pair A884(A752)-U2978(U2609) and forms bridging interaction with water
W2 (light blue) and O6 of G880(G748). d Superposition of TEL bound to the E. coli ribosome (green, PDB ID 4V7S15) with TEL (salmon) in complex with
the S. cerevisiae 60S subunit (Sc60S) bearing the G2400A mutation. E. coli rRNA and ribosomal protein residues are light green, yeast rRNA and protein
residues are gray.
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experiments (Fig. 2d). The hydroxyl group of the desosamine
forms a hydrogen bond interaction with the N1 of A2400,
whereas the dimethylamino group appears to interact with the
exocyclic N6 amine group of A2400 via a water molecule (W1)
(Fig. 3c and Supplementary Fig. 4f), as reported previously for
ERY43. The alkyl–aryl side chain of TEL is stretched in the
opposite direction with its aromatic moiety stacked upon the base
pair formed by A884 (752) and U2978 (2609) (Fig. 3c and
Supplementary Fig. 4g), similar to that observed for TEL binding
to E. coli (Fig. 3d), T. thermophilus and B. subtilis
ribosomes15,16,44, and distinct from its placement in the
ribosomes of the bacterium Deinococcus radiodurans (Berisio,
2003 #4141;Schlunzen, 2003 #3935) and the archaeon Haloarcula
marismortui (Tu, 2005 #4874) (Supplementary Fig. 5a, b). We
also detect additional density that would be consistent with a
water molecule (W2) forming a bridging interaction between the
side chain of TEL and the O6 of G880 (748) of the 25S rRNA
(Fig. 3c and Supplementary Fig. 4g), and helping to orient the
alkyl-aryl appendage for its interaction with the A884 (752)—
U2978 (2609) base pair. Curiously, in the yeast 60S-TEL
structure, the aromatic rings of the alkyl-aryl side chain are
non-planar and rotate with respect to each other, thereby
enabling an optimal stacking interaction with the nucleobases
of A884 and U2978—which are themselves non-planar (Fig. 3c).
In all previous structures of TEL complexed with bacterial or
archaeal ribosomes14–16,36,44,45, the alkyl-aryl moiety has been
modeled in a planar conformation, regardless of whether the
A884-U2978 base-pair is planar or not (Fig. 3d and Supplemen-
tary Fig. 6a, b). It remains unclear whether these distinctions are
due to species-specific differences or the limited resolution in
some of the previous structures. Comparison of the yeast 60S-
TEL complex determined here with vacant yeast 80S ribosomes46,
did not reveal any significant conformational change within the
25S rRNA nucleotides that comprise the TEL binding site
(Supplementary Fig. 5c). Thus, it is TEL that adjusts its
conformation to establish optimal interactions with the ribosomal
site, rather than requiring reorientation of the ribosomal residues
for the optimal fit. Mutating in silico A2400 back to G in our
structure or aligning the TEL-60S complex with the vacant wt
yeast 80S ribosomes46, suggests that the N2 position of G2400
would mildly clash with the desosamine sugar of TEL
(Supplementary Fig. 7). In addition, the presence of wt G2400
would preclude establishing the water (W1) mediated interaction
of the dimethylamino group of TEL with this 25S rRNA residue
(Supplementary Fig. 7b), as observed for ERY on bacterial
ribosomes43. Collectively, these observations provide a rationale
for the reduced affinity of TEL to wt yeast ribosomes
(Supplementary Fig. 2b), and pave the way for rational design
of macrolides that could be active against wt eukaryotic
ribosomes.
Macrolides elicit context-specific ribosome stalling in yeast
cells. Having demonstrated that macrolides can interfere with
translation by binding in the NPET of the mutant eukaryotic
ribosome, we wanted to know whether, similar to their action in
bacteria10,20,21, they preferentially arrest the ribosome at specific
sequence motifs. To address this question in an unbiased way, we
analyzed re-distribution of ribosomes on the mRNAs in the TEL-
exposed S. cerevisiae cells by ribosome profiling (Ribo-seq)47. In
order to minimize secondary stress-related effects, the exponen-
tially growing G2400A yeast cells were exposed for only a brief
time (10 min) to a high concentration of TEL (1.5 mg/mL
equivalent to 8× MIC), that result in ~90% inhibition of protein
synthesis (Supplementary Fig. 8a, b). Under these conditions, the
polysome profile of the treated cells showed virtually no changes
in comparison with the untreated control (Supplementary
Fig. 8c). The Ribo-seq data were highly reproducible between the
biological replicates, when gene scores (the relative densities of
ribosome footprints mapped to a gene) or pause scores (the
relative codon occupancies) were compared (Supplementary
Fig. 8d–f). However, comparison of TEL datasets relative to the
controls showed a number of sites with a notably increased pause
score in the antibiotic-treated samples, reflecting a redistribution
of ribosomes within mRNAs in response to the exposure to the
drug (Supplementary Fig. 8g–i). This could be clearly observed in
individual ORFs, where exposure to TEL caused a significant
increase in the ribosomal occupancy of specific codons (Fig. 4a),
revealing drug-induced stalling of translation at defined sites
within coding sequences. At the same time, the distribution of
ribosomes within some other ORFs was barely affected by the
TEL treatment, suggesting that macrolides affect eukaryotic
translation in context-selective and protein-selective manner.
To determine whether specific sequence signatures are
associated with the sites of most prominent macrolide-induced
translation stalling, we applied pLogo analysis48 to 749 sites
where the relative ribosome occupancy (pause score) was ≥2.5-
fold higher in the TEL-treated cells compared to the control in
two independent biological replicates (Fig. 4b, upper right
quadrant). According to the location of the TEL binding site in
the NPET of the yeast ribosome (Fig. 3), the drug could make
contact with C-terminal residues of the nascent polypeptide6,49.
Therefore, we looked for a possible enrichment of specific amino
acids within the nine C-terminal residues of the nascent chains
(residues −1 to −8 and residue number 0 assigned to the P-site
amino acid) and, in addition, the incoming amino acid (position
+1, encoded by the codon located in the A site of the arrested
ribosome). There was a strong tendency for the prevalence of Pro,
Lys, or Arg as the penultimate residues of the nascent chain, and
of Lys (and to a lesser extent of Arg) as the incoming amino acid
(Fig. 4c). Fixing defined amino acid residues at a specified
position of the pLogo plot allowed the identification of the two
main TEL arrest motifs in yeast (Fig. 4d–h). The most common
motif (24% of the strong arrest sites) is represented by the
sequence Arg/Lys-X-Arg/Lys (where X, which could be any
amino acid, corresponds to the C-terminal residue of the nascent
peptide in the stalled ribosome) (Fig. 4d). The genome-wide
metagene analysis confirmed that TEL treatment leads to a
significant enrichment of ribosome footprints at the codon
specifying the middle amino acid of the Arg/Lys-X-Arg/Lys motif
(Fig. 4f, h). This pattern matches the one commonly found in
TEL-arrest sites in bacteria20,21 called the “+X+” motif11,21
because both Arg and Lys side chains carry a positive charge. The
second most prevalent motif, found in 15% of the strongest arrest
sites in yeast, is characterized by the presence of proline as the
penultimate amino acid of the nascent protein (Fig. 4e, h).
Because among such sites the most frequent C-terminal residue is
an aspartate (Fig. 4h), we designated this motif as PDX. Genome-
wide metagene analysis confirmed the general TEL-induced
ribosome stalling at the middle codon of the PDX arrest motif
(Fig. 4g).
Noteworthy, although the PDK sequence is one of the
preferred sites of TEL-induced arrest in bacteria21, the general
PDX sequence is not particularly problematic for the TEL-bound
bacterial ribosome11,21. While the variable X amino acid within
the +X+ and PDX motifs might play a secondary role, its identity
apparently modulates the efficiency of stalling (Supplementary
Fig. 9a, b). Importantly, not every +X+ or PDX sequence, even
when containing a favorable X amino acid within the motif, was
associated with increased ribosome occupancy in the TEL-treated
yeast cells (Supplementary Fig. 9c). Therefore, the general signal
of macrolide-induced stalling likely includes additional elements
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Fig. 4 Macrolides arrest translating ribosomes at specific sequences. a Examples of TEL-induced translation arrest within S. cerevisiae genes. Comparison
of ribosome footprint densities in untreated G2400A yeast cells (“no drug”, downwards extending black plots) or cells treated for 10min with 1.5 mg/mL
(8× MIC) of TEL (upwards-extending orange plots). The arrows indicate prominent footprint density peaks; the amino acid in the P site of the stalled
ribosome is shown in bold. b The correlation of pause score ratios in TEL-treated and untreated cells for 46,445 sites within the actively expressed genes
between two independent experiments. The red rectangle includes the 749 sites with ≥2.5-fold enrichment of ribosomal density in TEL samples in both
experiments, which were used for the pLogo analysis shown in c–e. The green rectangle marks the 1809 sites of the least efficient TEL action (pause scores
reduced by ≥2-fold in the TEL-treated samples). c pLogo analysis of the sequences of the nine C-terminal residues of the nascent protein (positions 0 to
−8) and the A-site amino acid (position +1) at the sites of strongest TEL action. d pLogo analysis of the sites of the strongest TEL action conforming to the
+X+ arrest motif. e pLogo analysis of the strongest arrest sites where proline (P) is present in the penultimate position of the nascent chain. f, g Bottom
panels: Metagene analyses of ribosome density around the +X+ (f) and PDX (g) arrest motifs in TEL-treated (orange plots) and untreated (black plots)
cells. Top panels show the ratio between the TEL and control metagene plots. The P-site codons of the +X+ and PDX motifs (highlighted by gray
shadowing) are assigned as position 0. Note that the large metagene peak upstream from the highlighted peak in the PDX plot results from TEL-
independent ribosome stalling at Pro codons54. h Relative occurrence of the different prevalent motifs among the 749 sites of strongest TEL-induced
arrest. Left pie-chart shows all 749 sites, middle chart represents the subset of sites conforming to the +X+ motif and the chart on the right illustrates the
subset of sites corresponding to the PXX motif.
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besides the identified short motifs. No well-defined sequence
motifs were detected for the remaining 61% of the strongest sites
of TEL-induced arrest that do not conform to the +X+ or PDX
motifs (Fig. 4h), except possibly for an increased incidence of the
presence of Lys and Arg in the P-site of the TEL-stalled ribosome
(Supplementary Fig. 9d).
We also analyzed the mRNA sites, where translation was least
sensitive to inhibition by TEL. Due to drug-induced redistribu-
tion of ribosomes on mRNAs, such codons are characterized by
diminished pause scores in the TEL-treated cells relative to the
control (Fig. 4b, lower left quadrant). The yeast ribosome is least
susceptible to TEL inhibition when the nascent chain contains
Asn at the C-terminus, or when Glu is the incoming amino acid
(Supplementary Fig. 9e, f). However, we did not find these two
residues to be associated in a single sequence context. Rather,
their effect on reducing TEL inhibition appeared to be
independent from each other (Supplementary Fig. 9f). Neither a
C-terminal Asn within the +X+ stalling motif, nor a Glu residue
in the PDX arrest sequence are able to counteract the TEL action
(Supplementary Fig. 9a, b), indicating that their effects are fairly
moderate in comparison with the impact of the arrest motifs on
translation when the drug is present.
Altogether, the Ribo-seq analysis revealed that in the
eukaryotic cell macrolides act as context specific inhibitors,
arresting translation preferentially at specific sequence motifs.
Extent of inhibition of protein expression by TEL depends on
the polypeptide sequence. Although Ribo-seq analysis showed
that TEL-bound yeast ribosomes stall at distinct sites during
translation of a gene, the redistribution of ribosome footprints on
mRNA does not directly reveal how the yield of the encoded
protein is affected. To explore whether the context specificity of
macrolide action can be manifested as sequence-selective inhibi-
tion of protein expression, we studied the effects of TEL on the
synthesis of individual proteins in a cell-free system driven by the
G2400A yeast ribosomes.
Cell-free expression of the Zeo1 protein, encoded by an ORF
where the ribosome footprints pattern remained unchanged in
the TEL treated cells, was barely affected even by high
concentrations of the macrolide (Fig. 5a, c). By contrast,
expression of the Slt2 polypeptide was highly sensitive to TEL
and instead of the full-size protein, a shorter (~11 kDa) product
accumulated (Fig. 5b, d). Appearance of the truncated Slt2
fragment possibly results from translation arrest at the PDG98
sequence of the SLT2 ORF (Fig. 5b, d) that conforms to the PDX
stalling motif.
To directly test whether the protein sequence impacts the
extent of inhibition of its translation by TEL, we followed
expression of the reporter, superfolder Gfp (Gfp), in a cell-free
system50. Five potential macrolide arrest motifs could be
recognized within the Gfp sequence, two of the PDX type
(PDH77 and PDN198) and three of the +X+ type, two of them in
tandem, KYKTR109, and the single KQK158 (Fig. 5e). Consis-
tently, in vitro synthesis of the full-length (26.7 kDa) Gfp was
inhibited by TEL in a concentration dependent manner (Fig. 5f).
Two distinct truncated polypeptides with apparent molecular
weights of ~12 kDa and ~22 kDa appeared, when the Gfp
template was expressed in the cell-free system in the presence
of TEL (Fig. 5f, g, green and blue arrows and asterisks). The
smaller product may originate from interruption of GFP
translation at the KYKTR109 site, whereas the accumulation of
the 22 kDa product could be caused by translation arrest at the
PDN198 sequence. To test these assertions, we introduced
mutations disrupting the predicted arrest sequences. Replacing
the Lys107 codon with an Ala codon (K107A mutation), converted
the encoded KYK107TR sequence to KYA107TR and thereby
eliminated both overlapping +X+ motifs. When this mutant
template was translated in the presence of TEL, the 12 kDa
peptide no longer appeared (Fig. 5g, compare lanes 2 and 4),
confirming that the wt KYKTR109 sequence was the site of the
drug-induced translation arrest. Similarly, inactivation of the
PDX motif by mutating the Pro196 codon within the PD197N
sequence to the Ala codon (P196A mutation) abolished the
appearance of the 22 kDa product (Fig. 5g, compare lanes 2 and
6). The double K107A/P196A mutant that lacked both of the
aforementioned macrolide arrest sites in GFP, prevented
accumulation of both the 12 and 22 kDa truncated polypeptides
and rendered translation of the full-size protein highly resistant to
inhibition by TEL (Fig. 5g, compare lanes 2 and 8). In an
independent assay, where Gfp expression was monitored by
following its fluorescence, even at concentrations of TEL as high
as 100 µM, translation of the full-size protein carrying the K107A/
P196A mutations remained at ~75% of the control, whereas
production of wt Gfp was reduced to a lesser than 20% level
(Fig. 5h). These results demonstrate that inhibition of protein
production by binding of a macrolide to a eukaryotic ribosome
critically depends on the sequence of the translated polypeptide,
and revealed macrolides as potential protein-selective inhibitors
of eukaryotic translation.
Context-specific inhibition of translation depends on the
structure of the macrolide antibiotic. We asked whether varia-
tion in the structure of the drug bound in the NPET of the yeast
ribosome would affect specificity of translation inhibition. Several
representative extended macrolides differing in the structure of
the macrolactone ring and side chains were selected for these
experiments (Fig. 6a). RNA chemical probing showed that in
contrast to ERY or AZI, all these extended macrolides efficiently
bind to the mutant yeast ribosome, and protect the A2400 and
A2401 residues (A2058/A2059) from DMS modification (Fig. 6b
and Supplementary Fig. 2c). Tylosin (TYL) and spiramycin (SPI),
that carry a C5 disaccharide side chain (boxed in Fig. 6a), addi-
tionally protected A2404 (A2062) (Fig. 6b). Such protection,
caused by a direct interaction of the drugs’ C5 side chain with this
nucleotide, which has been noted previously in archaeal and
bacterial ribosomes51,52, is indicative of a similar binding mode of
these drugs in the eukaryotic ribosome.
We then examined the effects of all these antibiotics on the
in vitro synthesis of three different polypeptides (the Gfp reporter
and the two yeast proteins Slt2 and Zeo1), that we used in the
previous experiments (Fig. 5). Strikingly, different drugs affected
protein synthesis in a very distinct fashion. The C3-cladinose-
containing compounds RU69874 and CEM103 efficiently blocked
the expression of all three proteins, including TEL-resistant Zeo1
(Fig. 6c–e). Because no accumulation of truncated peptides was
observed, these inhibitors possibly block protein synthesis at very
early stages of cell-free translation. TEL, SOL, cethromycin (CET),
and RU3004, all of which carry the C3-keto group instead of
cladinose, had only a small effect on expression of Zeo1 (Fig. 6e),
but readily inhibited translation of Gfp and Slt2 (Fig. 6c, d). As we
had observed with TEL (Fig. 5d, f, g), SOL, CET, and RU3004 caused
accumulation of specific truncated polypeptide products due to
translation arrest at the identified macrolide arrest motifs within the
Slt2-coding and Gfp-coding sequences. The remaining two drugs,
16-membered ring TYL and SPI with C5 disaccharide side chains
barely affected expression of the tested proteins in the cell-free
system (Fig. 6c–e) in spite of the robust binding of these
compounds to the G2400A ribosome (Fig. 6b). The efficient
synthesis of full-length polypeptides potentially reflected the ability
of the yeast ribosomes to polymerize the problematic motifs
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-23068-1 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:2803 | https://doi.org/10.1038/s41467-021-23068-1 | www.nature.com/naturecommunications 7
regardless of the presence of these drugs. TYL and SPI also failed to
inhibit growth of the mutant yeast cells (Supplementary Table 1).
Taken together, our data indicate that by altering the structure
of macrolide antibiotics bound to the eukaryotic ribosome it is
possible to modulate their effect upon synthesis of individual
proteins.
Discussion
In this study, we demonstrated that binding of macrolide anti-
biotics in the NPET of a mutant yeast 80S ribosome inhibits
protein synthesis in a context-specific manner. Two major
sequence motifs, +X+ and PDX, were identified as problematic
for polymerization by the TEL-bound yeast ribosome. Elimina-
tion of the arrest sequences significantly improved the expression
of an otherwise drug-sensitive protein in the presence of the
antibiotic. These results establish macrolides as prospective
protein-selective inhibitors of eukaryotic translation.
The main arrest motif in yeast, +X+, is identical to the pri-
mary motif of macrolide-induced stalling in bacteria20–22,25. The
second motif, PDX (or more generally, PXX) appears to be more
specific for the eukaryotic cytoplasmic ribosome. Although pro-
lines are also found in some of the macrolide arrest motifs in
bacteria, they are most commonly placed in the P or A sites of the
stalled ribosome11,20,21. In contrast, in the TEL-bound yeast
ribosome, the presence of proline in the penultimate position of
the nascent protein creates a hurdle for translation. Importantly,
neither in bacteria, nor in yeast, the nascent chain residues critical
for the drug-induced ribosome stalling are juxtaposed with the
drug molecule in the NPET. Instead, they are located at the PTC
or in its immediate vicinity. Thus, in eukaryotes, just like in
bacteria, TEL appears to act as an inhibitor of peptide bond
formation between specific donor and acceptor substrates rather
than as a discriminating gateway for the growing protein chain.
Interestingly, both macrolide arrest motifs, +X+ and PDX,
were found previously at the sites of ribosome pausing in yeast
cells depleted of the elongation factor eIF5A, which helps the
ribosome in polymerizing problematic combinations of amino
acids53–55. It is possible, therefore, that binding of TEL to the
yeast ribosome aggravates the burden of polymerizing
intrinsically-difficult sequences. Noteworthy, however, in the
untreated cells the ribosome often pauses at proline codons, with
the nascent chain ending with proline54 (Fig. 4g). TEL addi-
tionally pauses translation at the following codon, when a proline
residue is present in the penultimate position of the nascent
chain (Fig. 4g). The pLogo plots also showed a somewhat
increased presence of methionine at position −8 relative to the
Fig. 5 TEL selectively inhibits in vitro translation of proteins with specific sequence motifs. a, b Ribosome footprint density in the ZEO1 (a) and SLT2 (b)
genes in yeast cells treated (orange plots) or not (black plots) for 10 min with 8× MIC of TEL. PDX and +X+ motifs present in the SLT2 gene are indicated
by arrows. Increased ribosome occupancy at early codons of SLT2 (orange asterisk) occurs at sites not conforming to the +X+ or PDX motifs. c, d SDS-gel
analysis of the [35S]-radiolabeled proteins generated by in vitro translation of the ZEO1 (c) or SLT2 (d) templates by the G2400A yeast ribosome in the
absence of the drug or in the presence of 100 µM TEL. Arrowheads indicate full-size proteins. The truncated Slt2 polypeptide, likely a product of TEL-
mediated translation arrest at the PD98G motif, is indicated by an arrow and asterisk. e Locations of +X+ and PDX motifs in the GFP reporter gene. The
molecular weights (kDa) of the proteins whose translation would be terminated at the corresponding sites are indicated. f Top: SDS-gel analysis of the
[35S]-labeled products of in vitro translation of the GFP template in the absence or presence of increasing concentration of TEL. The band of the full-size
Gfp is indicated. Truncated Gfp polypeptides resulting from TEL-induced ribosome arrest are marked with arrows and asterisks (colored as shown in
e. Bottom: quantification of the relative radioactivity associated with the full-size and truncated Gfp polypeptides in the SDS gel above. g SDS-gel analysis
of the in vitro translation products of the wild-type (WT) GFP gene or its mutant variants in the absence or presence of 100 µM TEL. Translation products
are labeled as in f. h Expression of wt Gfp (Gfpwt) or its K107A/P196A mutant (Gfpmut) in the yeast cell-free translation system in the presence of increasing
concentrations of TEL. Accumulation of functional Gfp was followed by its fluorescence. The activity of Gfpwt in the “no-drug” samples was set at 100%.
The curves represent average of two independent experiments with individual data points indicated by filled (Gfpwt) or open (Gfpmut) circles. The
uncropped gel can be found in the Source data file. The results shown in c, d, f, and g are typical representatives of at least two independent experiments.
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site of TEL-induced arrest (Fig. 4c–e and Supplementary Fig. 9d).
However, this effect may simply reflect the fact that in the ten
amino acid window that we used in our analysis, the initiator Met
will be always found at this position when the window is placed at
the beginning of the ORFs.
The macrolide arrest motifs identified by our bioinformatics
analysis likely represent only a part of the signal required for the
drug-induced ribosome stalling. Indeed, the Ribo-seq data
revealed that the TEL-bound ribosome stalls only at a fraction of
the sequences matching the identified arrest motifs. This con-
clusion was additionally reinforced by our in vitro translation
experiments, where only some of the +X+ or PDX sequences
caused accumulation of the corresponding truncated polypeptides
(Fig. 5f, g). These observations argue that other factors, operating
at the level of the polypeptide chain, mRNA or tRNA might be
also at play. In particular, more remote segments of the nascent
protein, within or even outside of the NPET, could suppress or
stimulate the arrest imposed by the tunnel-bound antibiotic,
similar to the influence of the distal nascent chain context on
ribosomes pausing during polymerization of polyproline
sequences56,57 or of the native stalling peptides58,59.
The effect of macrolides on eukaryotic translation critically
depends on the structure of the NPET-bound antibiotic (Fig. 6).
The ketolides (macrolides with a C3-keto group) exhibit strong
context dependence of the translation arrest (Fig. 6c–e). Similar
compounds but with a C3 cladinose inhibit protein synthesis but
do not yield any truncated protein products, likely because they
interfere with the very early stages of translation (Fig. 5c–e).
Strikingly, the 16-member macrolactone ring containing drugs
TYL and SPI, in which a disaccharide moiety replaces the C5
desosamine present in other tested macrolides, had only limited
effect on the yield of the three tested proteins (Fig. 6c–e). One
possibility is that the advancing N-terminus of the growing
polypeptide could displace TYL or SPI from their binding site, as
has been suggested for the mode of action of short macrolide
resistance peptides in bacteria60–62. Alternatively, these anti-
biotics could be much more selective compared to ketolides and
the three proteins used in our in vitro experiments simply lacked
the required arrest motifs. Noteworthy, some reports alluded that
TYL could induce premature stop codon readthrough in
mammals63, suggesting a possible effect of the antibiotic on
translation in the wt eukaryotic cell, although it remains
unknown whether this activity was mediated by binding of the
drug to the ribosome.
Besides macrolides, the only other known highly-selective
protein synthesis inhibitor acting upon the eukaryotic ribosome is
the compound PF846, which interferes with translation of a very
narrow subset of proteins in mammalian cells5. The binding site
of PF846 in the NPET partially overlaps with that of macrolides
(Supplementary Fig. 10), but its specificity and mode of action are
significantly different. In contrast to TEL, which arrests transla-
tion at distinct sites, PF846 slows down the progression of the
ribosome over several consecutive mRNA codons at the site of
arrest5–7. At each of these codons the ribosome operates with a
different combination of donor and acceptor ligands and there-
fore, in contrast to TEL, PF846 specificity is less dependent on the
nature of the PTC substrates, but rather on the unusual trajectory
of the nascent chain in the NPET6,7. Consistently, while macro-
lides inhibit peptide bond formation24–27, PF846 interferes with
ribosome translocation and with translation termination6,7. It is
remarkable that in spite of these differences, PF846 and TEL
achieve context-specific inhibition of translation by binding to
overlapping sites in the NPET. Interestingly, it has been recently


























































































































































































































































































































Fig. 6 The structure of the macrolide affects selective inhibition of translation. a Structures of representative macrolide antibiotics grouped according to
their chemical features: group I, 14-atom macrolactone ring carrying C3 cladinose sugar (framed in red); group II, 14-atom macrolactone ring with C3 keto
group (red arrow) and extended alkyl-aryl side chain (gray arrow); group III, 16-member macrolactone with C5 disaccharide chain (framed in red).
b Chemically different macrolides readily bind to the yeast G2400A mutant ribosome as revealed by the protection of 25S rRNA residues A2400(2058),
A2401(2059) and, in the case of the group III compounds, A2404(2602) from DMS modification. The drugs were present at 100 µM. The primer
extension products were resolved in the denaturing 6% polyacrylamide gel. Control samples (“NONE”) contained no macrolides. c–e SDS-gel analysis of
the [35S]-labeled protein products accumulated during translation in the yeast cell-free system of templates encoding the Gfp reporter (c) or the Slt2 (d),
and Zeo1 (e) yeast proteins. Translation reactions were supplemented with 100 µM of the indicated macrolides. The control reaction (NONE) contained no
antibiotic. Arrowheads and arrows/asterisk represent the bands corresponding to the full-length and truncated products, respectively. The uncropped gel
can be found in the Source data file. b–e Representative gels of two independent experiments.
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and eukaryotic ribosomes in a cavity of the NPET located on the
wall opposite to the macrolide binding site and appears to act, at
least during bacterial translation, in a sequence-specific manner64.
Therefore, the PTC-proximal NPET segment emerges as the best
target for the inhibitors, whose action depends on the sequence
context of the growing polypeptide.
Identifying compounds capable of selectively suppressing
expression of unwanted proteins, especially those that are viewed
as “undruggable targets”, is an attractive strategy for the devel-
opment of new medicines. For example, upregulation of expres-
sion of ribosomal proteins uL6 (gene RPL9), eL15 (RPL15), and
eL39 (RPL39) is associated with increased tumor growth and
metastasis in some cancers65–67. Our Ribo-seq analysis showed
that some of the strongest sites of TEL-induced translation arrest
in yeast are located within the ORFs encoding these proteins
(Supplementary Fig. 11a, b), and these sequences are highly
conserved in the corresponding human genes (Supplementary
Fig. 11c). Thus, macrolide derivatives capable of selective inhi-
bition of expression of these and other oncoproteins could inform
the advancement of new cancer therapies.
In our study, we used several available macrolides which have
been specifically selected or optimized by the pharmaceutical
industry for their action upon the bacterial ribosome and the lack
of the effects upon eukaryotic translation. Therefore, we were
compelled to carry out our experiments with the yeast ribosome
that was intentionally sensitized to macrolide action by introdu-
cing the G2400A substitution in the drug-binding site. This
single-nucleotide mutation allowed for binding with considerable
affinity of several macrolide antibiotics with extended side chains.
Noteworthy, some macrolides (e.g., TYL or SPI) are capable of
binding to the NPET of the archaeal ribosomes51, in spite of the
eukaryote-like nature of their macrolide-binding site. These
observations argue that a targeted drug optimization, especially if
guided by high-resolution structural data, could yield macrolide-
inspired compounds active against the unaltered eukaryotic
cytoplasmic ribosome. The recent progress in synthetic chemistry
of macrolides68 makes obtaining such compounds within a
realistic reach.
Methods
Reagents and radiochemicals. All chemicals were from Thermo Fisher Scientific
or Sigma-Aldrich. Radiochemicals were from PerkinElmer ([35S]-L-methionine and
[32P]-γ-ATP), American Radiolabeled Chemicals ([14C] ERY) or Cempra Phar-
maceuticals ([14C] SOL). Premixed media and media components for yeast and
bacteria growth were from Difco. Macrolide antibiotics used in the study were
purchased from Sigma-Aldrich or obtained from Aventis or Cempra
Pharmaceuticals.
Yeast strains and plasmids. S. cerevisiae strain NOY89138 and plasmid pJD69469
were kindly provided by Dr. Dinman (University of Maryland). S. cerevisiae
NOY891 (MATa ade2-1 ura3-1 leu2-3 his3-11 trp1 can1-100 rdn1ΔΔ::HIIS3) car-
ries the TRP1-selectable plasmid pNOY353, that contains the wild type RDN
operon encoding 35S pre-rRNA under the control of GAL7 promoter38. Plasmid
pJD694 contains a URA3 selectable marker and carries the 35S pre-rRNA operon
under the control of the tetracycline (doxycycline) repressible TET promoter69.
The S. cerevisiae strain with the G2400A mutation in the 25S rRNA gene was
prepared as follows. The G2400A mutation was introduced in plasmid pJD694 by
overlap-extension PCR70, and the mutant plasmid was transformed into the
NOY891 strain71. Transformants were selected by first plating cells on SC-Ura-Trp
minimal media with 10 μg/mL of doxycycline (to select for the presence of plasmid
pJD694 but repress expression of the mutant 25S rRNA), followed by selection on
plates with complete YPD medium supplemented with 300 µg/mL of hygromycin B72.
Antibiotic sensitivity testing. S. cerevisiae strains were grown with shaking at 30 °
C in YPD medium supplemented with 100 µg/mL of ampicillin (Amp). Expo-
nentially growing cells were diluted with fresh medium to the final culture density
of A600= 0.005 and placed in 96-well plates (100 µL of culture per well). After
addition of increasing concentrations of macrolide antibiotics, plates were incu-
bated for 18 h at 30 °C. The minimal inhibitory concentration (MIC) was deter-
mined as the lowest concentration of antibiotic that prevented visible cell growth.
Inhibition of bulk protein synthesis in vivo. S. cerevisiae NOY891 G2400A
mutant cells were grown exponentially at 30 °C in YPD medium supplemented with
Amp. When the culture density reached A600 ~0.5, aliquots of 1.5 mL were trans-
ferred to 15mL polypropylene tubes (Falcon). A macrolide antibiotic, TEL or SOL,
was added to different final concentrations, which were ranging from 15 µg/mL
(0.08x MIC) to 6mg/mL (32x MIC) for TEL and from 1 µg/mL (0.02x MIC) to
1 mg/mL (20x MIC) for SOL. Control cultures were left without antibiotic. Cultures
were incubated with shaking at 30 °C for 10min and aliquots of 250 µL were
withdrawn to estimate protein synthesis rate by metabolic labeling. For this, cells
were collected by rapid centrifugation (1min at 14,000 × g), washed twice with SD
medium (8% Yeast Nitrogen Base, 2% glucose) containing the corresponding
concentrations of macrolide antibiotics and resuspended in 30 µL of fresh SD
medium supplemented with 40 µg/mL of each amino acid except methionine.
Reactions were initiated by addition of 1 µL of 11 µCi/µL of [35S]-L-methionine
(specific activity 1175 Ci/mmol). After 5 min incubation at 30 °C, 25 µL of the tubes’
contents were spotted onto ∅ 25mm Whatman 3MM paper disks. Disks were
immediately immersed into a beaker containing 500mL of 5% trichloroacetic acid
(TCA). Following collection of all samples, the content of the beaker with the disks
was boiled for 5 min and TCA was discarded. The TCA wash procedure was
repeated one more time. Disks were rinsed with acetone, dried, placed in vials with
5 mL of scintillation cocktail, and the amount of radioactivity retained was deter-
mined by scintillation counting. The time course of TEL-induced inhibition of bulk
protein synthesis was carried out following essentially the same protocol except that
the cultures were incubated with the antibiotic for 0, 5, 10, and 40min before
metabolic labeling was carried out.
Purification of yeast 80S ribosomes. S. cerevisiae G2400A mutant 80S ribosomes
were purified for the structural studies according to the published protocol73. The
ribosomes for the drug binding assays were purified using the same protocol except
that sucrose gradient fractionation was replaced with pelleting through a 30%
sucrose cushion in a buffer containing 20 mM Hepes-KOH, pH 7.5, 120 mM KCl,
8.3 mM MgCl2, 2 mM DTT, 0.3 mM EDTA. Specifically, ribosomes collected from
the lysate by sequential differential precipitation with PEG 20 K (4% and then 9%
w/v) were resuspended in 15 mL of buffer A (30 mM Hepes-KOH, pH 7.5, 150 mM
KCl, 10 mM MgCl2, 8.5% mannitol, 2 mM DTT, 0.5 mM EDTA), layered over a
15 mL sucrose cushion, and centrifuged for 16 h in a Ti-70 rotor (Beckman) at
36,000 rpm (130,000×g) at 4 °C. The ribosome pellets were resuspended in a sto-
rage buffer containing 10 mM Hepes-KOH, pH 7.5, 50 mM KOAc, 10 mM NH4Cl,
2 mM DTT, 5 mM Mg(OAc)2, flash frozen in liquid nitrogen and stored at −80 °C.
Analysis of binding of macrolides to yeast ribosomes. Purified ribosomes were
diluted to 80 nM (A260= 4) and combined with varying concentrations of [14C]-
SOL (specific activity 53 Ci/mol) in 100 µL of binding buffer (80 mM Hepes-KOH,
pH 7.5, 140 mM KCl, 1.5 mM DTT, 5 mM MgCl2). The reactions were incubated
for 1 h at 30 °C. Following incubation, ribosomes were captured using 0.5 mg
diethyl amino ethyl (DEAE) magnetic beads (BioClone). Beads were rapidly
washed three times with 1 mL of ice-cold binding buffer and then resuspended in
100 µL of 1% SDS as described74. Ribosome-associated radioactivity was deter-
mined by scintillation counting. Data were analyzed using Prism software
(GraphPad).
Analysis of binding of unlabeled drugs to ribosomes was performed by RNA
chemical probing following the conventional procedure41, but with minor
modifications. Briefly, ribosomes (final concentration 0.2 µM) and antibiotic (final
concentration 100 µM) were incubated in 50 µL of binding buffer for 1 h at 30 °C.
Two microliters of dimethylsulfate (DMS) diluted 1:5 in ethanol were added to the
reactions and incubation continued for additional 10 min at 30 °C. The reactions
were quenched by addition of 50 µL of stop solution containing 0.6 M NaOAc and
1M β-mercaptoethanol. Ribosomes were ethanol-precipitated and rRNA was
extracted. The extent of modifications of 25S rRNA residues in the macrolide
binding site was assessed by primer extension using the 5′-[32P]-labeled primer
25S-2430 (Supplementary Table 3).
Cryo-EM and single-particle reconstruction of 60S-TEL complex. The 80S-TEL
complex was generated by incubating purified ribosomes with 50 µM TEL for 15
min on ice in buffer 10 mM Hepes-KOH, pH 7.5, 50 mM KOAc, 10 mM NH4OAc,
2 mM DTT, 5 mM Mg(OAc)2. Four microliters of the reaction solution (absor-
bance A260= 5) were applied to pre-coated Quantifoil holey carbon supported
grids (R3/3, 3 nm C, Cu 300 mesh, Q44689, C3-C18nCu30-01) and vitrified using a
Vitrobot Mark IV (FEI). Data collection was performed on Titan Krios 300 kV
TEM equipped with a K2 direct detection camera (Gatan). Images of single ribo-
some particles were aligned using MotionCor275 and 329,333 particles were picked
automatically using Gautomatch (https://www.mrc-lmb.cam.ac.uk/kzhang/) with
an 80S ribosome (PDB ID 6S4776) as a reference and using default settings.
Defocus values were determined using Gctf software77 (https://www.mrc-lmb.cam.
ac.uk/kzhang/). Images were processed with Relion 3.078. Picked particles were
sorted by 2D classification and 242,959 ribosome-like particles were selected for
initial 3D refinement using an S. cerevisiae 80S reference structure (PDB ID 6S4776)
(Supplementary Fig. 3a). 3D classification yielded five classes with one class con-
taining 80S ribosomes with only E-site tRNA (75,303 particles), three classes with
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80S ribosomes and sub-stoichiometric E-site tRNA (combined 153,893 particles)
and one lower resolution class with sub-stoichiometric E-site tRNA (13,763)
(Supplementary Fig. 3b–d). Particles of combined classes 2–4 were 3D refined and
resolution optimized by CTF refinement through Relion 3.0 resulting in an average
resolution of 3.1 Å (unmasked) and 2.9 Å (masked) determined using the “gold-
standard” criterion (FSC0.143) (Supplementary Figs. 3e and 4a, left). Final 3D
reconstructions were corrected for the modulation transfer function and sharpened
by applying a negative B factor estimated by Relion 3.0. ResMap79 was used for
local resolution estimations.
Molecular modeling of 60S-TEL complex. The molecular model of the 60S
ribosomal subunit, containing ribosomal proteins and rRNA, were based on S.
cerevisiae 80S ribosome (PDB ID 6Q8Y46) and the molecular model of TEL was
based on E. coli 70S-TEL (PDB ID 4V7S15). Models were rigid body fitted into the
electron density map using Chimera80. The models were manually adjusted and
refined using Coot81, while regions with poor density were not manually adjusted
based on the initial model. The final model was refined using Phenix82 with
structural restraints calculated by Phenix eLBOW83. Model validation was carried
out using Phenix and MolProbity Server84 (http://molprobity.biochem.duke.edu/).
The map vs. model cross correlation at FSC0.5 was calculated by Phenix (1.19.2-
415882) comprehensive cryo-EM validation85 for each map individually using the
final molecular model (Supplementary Fig. 4a, right). The statistics of the final
model are presented in Supplementary Table 2.
Preparation of figures with Cryo-EM structures. Figures were generated using
PyMOL (Schrödinger, LLC) and structural superpositions were generated by
alignment to the bacterial or mammalian large ribosomal subunits. Isolated den-
sities and density images were created using Chimera80 and visualized using
ChimeraX86.
The structures of the NPET surfaces (Supplementary Fig. 1c) were generated
using the described algorithm87 with the following parameters: 60 Å cubic grid with
adjacent grid points separated by 1 Å; 10 Å sphere radius for creating an outer shell
of the large ribosomal subunit; 3 Å sphere radius for “filling-up” the internal
cavities of the ribosome, including NPET. The image was generated using PyMOL
(Schrödinger, LLC).
Preparation of samples for Ribo-seq. Two independent experiments (carried out
on different days and employing different library preparation protocols) were
carried out for collecting the Ribo-seq data. S. cerevisiae G2400A mutant cells were
grown exponentially at 30 °C in two 1 L flasks each containing 200 mL of YPD
medium. When the culture density reached A600 ~ 0.6, TEL was added to the final
concentration of 1.5 mg/mL (8x MIC) to one of the flasks. Cultures were incubated
with shaking for 10 min and cells were collected by rapid filtration through Express
Plus® Membrane filter (Millipore) as described88. Cells were rapidly frozen in
liquid nitrogen and lysed using Mixer Mill MM400 (Retsch) with 300 µL of lysis
buffer (10 mM Hepes-KOH, pH 7.5, 50 mM KOAc, 10 mM NH4Cl, 2 mM DTT, 5
mM Mg(OAc)2) without addition of cycloheximide. Lysates were cleared by cen-
trifugation (10 min 20,000 × g at 4 °C) and supernatants were treated with 30 U/
A260 of RNaseI (Ambion) at 4 °C for 5 min. Three hundred microliter of digested
lysates were loaded onto 500 µL of 25% (w/v) sucrose cushion in buffer 20 mM
Tris-HCl, pH 8.0, 140 mM KCl, 10 mM MgCl2 supplemented with 1× Complete
protease inhibitor. Ribosomes were pelleted by centrifugation in a TLA100.2 rotor
at 90,000 rpm (350,000 g), 4 °C for 1 h. Pellets were resuspended in 1% SDS and
ribosome-protected mRNA fragments were isolated by phenol-chloroform
extraction followed by electrophoresis in 15% denaturing gel. RNA footprints
ranging in size between ~20 and ~35 nt were excised from the gel, eluted and
converted to sequencing libraries as described by Becker et al.89 (for replicate 1) or
McGlincy & Ingolia88 (for replicate 2). The libraries were sequenced at the NUSeq
Core (Northwestern University) on Illumina HiSeq 4000 platform.
Computational processing of ribosome profiling data. Ribosome profiling data
were processed following the described algorithms88,90. Briefly, the fastq files were
first trimmed to remove linkers and, when necessary, demultiplexed to obtain
individual samples from pooled data using CUTADAPT91. To remove tRNA and
rRNA reads, the files were then aligned to an index of noncoding RNAs with
BOWTIE (version 1.1.2)92 using the following parameters: -v 2 -y. The fastq files
after noncoding RNA removal step were then aligned to coding regions and splice
junctions using BOWTIE (version 1.1.2)92 with the following parameters: -v 2 -y -a
-m 1—best—strata (two mismatches allowed and multiple alignments suppressed),
and using the R64-1-1 S288C reference genome assembly (SacCer3, Saccharomyces
Genome Database Project). Only 25–34 nt footprints were included in the analysis.
3′ alignments of the footprints were generated and used for subsequent analysis.
Reads per million (rpm) was computed by normalizing the read count at each
nucleotide position by the total number of mapped reads and then multiplying that
value by 106.
Metagene analysis. Metagene plots were constructed by calculating the average
(normalized by the total rpm in a window around the site of interest of the 100 nt
centered at the middle codon of the motif. Genes with features smaller than the
window size were excluded.
Calculation of pause scores. Pause scores were generated by dividing the rpm
associated with each nucleotide by the average rpm of the gene. TEL-induced
pauses were calculated by dividing the pause scores obtained from TEL-treated
cells by the pause scores in untreated cells. Nucleotides with at least 0.5 were
included in the analysis. The change in pause scores resulting from TEL treatment
was calculated by computing the average pause score per codon, and then dividing
codon pause score in the TEL sample by the codon pause score in the untreated
sample.
Gene scores were calculated by adding together the total rpm mapping to each
coding sequence. Reads were shifted by 18 nt from their 3′ ends to map the P-site.
Total number of reads for each gene were normalized by length of the gene (by
dividing by the length in kilobases) to obtain rpkm values (gene scores).
Analysis of the amino acid context enrichment at the sites of TEL-induced
ribosome stalling. The 10-amino acid long sequences associated with the sites of
the most pronounced TEL-induced translation arrest were computationally
extracted. Each sequence included amino acids encoded by the eight codons pre-
ceding the codon positioned in the ribosomal P site, and by the P-site and A-site
codons. The sequences associated with the sites showing ≥2.5-fold change in pause
score in both TEL samples compared to the control were compared to the amino
acid sequences associated with all the codons (46,445 in the 8× MIC sample)
included in the analysis using the pLogo tool48.
Preparation of yeast lysate and in vitro translation. The yeast lysate for in vitro
translation was prepared according to a procedure described by Hodgman et al.93
with minor modifications. The S. cerevisiae NOY891 G2400A mutant cells were
grown at 30 °C in 1 L of YPD medium supplemented with 100 µg/mL Amp. Upon
reaching an absorbance of A600 ~ 0.7, cells were harvested by fast filtration, flash-
frozen in liquid nitrogen and lysed using Mixer Mill MM400 (Retsch) as described
above for ribosome profiling. All following steps were carried out at 4 °C. The lysate
was clarified by centrifugation at 20,000×g for 5 min and the supernatant (~1 mL)
was desalted by gravity-flow gel-filtration through a 15 mL Sephadex G-25 column
equilibrated in buffer containing 30 mM Hepes-KOH, pH 7.6, 100 mM KCl, 2 mM
DTT, 0.5 mM PMSF, and 2 mM Mg(OAc)2. The flow-through fractions with
A260 ≥ 10 were combined, flash-frozen in liquid nitrogen, and stored at −80 °C.
Prior to using the lysate for in vitro transcription–translation assays, the
endogenous mRNAs were removed by nuclease treatment. For that, 50 µL of the
thawed lysate were supplemented with 1 mM CaCl2 and 3.5 units of micrococcal
nuclease (Thermo Fisher Scientific) and incubated for 10min at room temperature.
The reaction was quenched by addition of 2 mM EGTA and the lysate was
immediately used for in vitro protein expression. Reactions were carried out in a
total volume of 15 µL containing 7.5 µL of the nuclease-treated lysate supplemented
with the following components (listed with their final concentrations): 22 mM
Hepes-KOH, pH 7.6, 5.5 mM magnesium glutamate, 120mM potassium glutamate,
1.7 mM DTT, 1.5mM ATP, 1.5 mM GTP, 1.5 mM CTP, 1.5 mM UTP, 25mM
creatine phosphate, 0.26 mg/mL creatine kinase, 80 µM of each amino acid except
methionine, 0.6 µCi/µL of [35S]-L-methionine (specific activity 1175 Ci/mmol) and
50 µg/mL of T7 RNA polymerase purified according to Durniak et al.94. The
reactions were initiated by addition of 0.1 µg of the DNA templates prepared as
described below. The reaction products were analyzed in 16 % SDS gels. Gels were
fixed with 5% perchloric acid, stained with Coomassie blue, dried, and exposed
overnight to a phosphorimager screen. Radioactivity was visualized in a Typhoon
scanner (GE Healthcare). The intensity of the bands was quantified using ImageJ95.
Preparation of DNA templates for in vitro transcription/translation. The DNA
templates for the coupled transcription/translation reactions contained the 5′-
untranslated region of tobacco mosaic virus RNA (also known as Ω leader 5′-
GUAUUUUUACAACAAUUACCAACAACAACAAACAACAAACAACAUUA
CAAUUACUAUUUACAAUUACA-3′)96, followed by the protein coding
sequence of the analyzed gene, and ending with a poly-A tail. All the primers used
for generation of the templates are shown in Supplementary Table 3. To generate
the SLT2 and ZEO1 templates, the gene sequences were PCR-amplified from
genomic DNA of S. cerevisiae strain NOY891 using the primers Ω-SLT2/SLT2-A30
and Ω-ZEO1/ZEO1-A30, respectively. One microliter of the PCR product was
diluted 1:100 to then re-amplify it using the T7+ T7-Ω primers combined with
reverse primer SLT2-A30, for the SLT2 template, or with ZEO1-A30 primer for the
ZEO1 template. The GFP gene was PCR-amplified from the pJL1-sfGFP plasmid97
using primers Ω-sfGFP and sfGFP-reverse. The resulting PCR product was re-
amplified using primers T7, T7-Ω, and sfGFP-A37. The mutant GFP templates
were generated by introducing the desired mutations via cross-over PCR98 using
the respective mutagenizing primers listed in Supplementary Table 3 in combi-
nation with the T7 and sfGFP-A37 primers. The PCR products were cloned in
pUC18 plasmid and the presence of the desired mutations was verified by
sequencing. The templates for transcription-translation reactions were generated
by PCR from the corresponding plasmids using the primers T7 and sfGFP-A37.
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Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data that support this study are available from the corresponding authors upon
reasonable request. The cryo-EM and associated molecular model for the S. cerevisiae 80S
ribosome complexed with telithromycin is available from the EMDB (EMD-11951
[https://www.ebi.ac.uk/pdbe/entry/emdb/EMD-11951]) and PDB (7AZY [https://doi.
org/10.2210/pdb7AZY/pdb]), respectively. Ribo-seq data have been deposited in the
NCBI Gene Expression Omnibus (GEO) database under accession code GSE164275.
Source data is provided with this paper.
Code availability
The software used for the analysis of Ribo-seq data is available from https://github.com/
guydoshlab/Yeastcode1.
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